Shares of Laurus Labs surged over 6% intraday in early trade on Monday, May 4, to hit their 52-week high mark after D-Street brokerages maintained a bullish stance as the pharmaceutical major reported a strong performance during the January-March quarter for fiscal 2025-26 (Q4FY26) driven by CDMO-led growth volumes. According to NSE data, the stock trades at its highest price in the last one year after brokerages such as HDFC Securities and Choice Institutional Equities hiked the target price for Laurus post Q4 results, largely driven by the CDMO-led growth volumes and robust consistency across business segments.
On Monday, shares of Laurus Labs opened at Rs 1,102.20 and surged over 6% to hit an intraday and 52-week high of Rs 1,169.80 apiece on the NSE after bullish outlook from domestic brokerages. Shares last traded 5.98% higher at Rs 1,166.30 apiece on the NSE. Shares of Laurus Lab have gained 11.23% in one month, 5% on a year-to-date basis, and 87% in the last one year. The pharma company commands a market cap of Rs 62,936.48 crore, according to stock exchange data.
Essential Business Intelligence, Continuous LIVE TV, Sharp Market Insights, Practical Personal Finance Advice and Latest Stories — On NDTV Profit.
